From the Division of Cardiology, The Warren Alpert Medical School of Brown University, Providence, Rhode Island.
Department of Cardiology, Massachusetts General Hospital, Boston, MA.
Crit Pathw Cardiol. 2020 Jun;19(2):87-89. doi: 10.1097/HPC.0000000000000210.
Hypertrophic cardiomyopathy (HCM) is 1 of the most frequent genetic cardiovascular diseases affecting 1 out of every 500 individuals in general population. Atrial Fibrillation incidences were 3.8% per 100 patients per year and overall prevalence among HCM patients are 27.09%. Higher risk of death noted in HCM patients with atrial fibrillation. Stroke and other thrombo embolic risks are increased in such patients. Medical management using mainly betablockers or amiodarone produced variable results and high rate of recurrence. Catheter ablation reduced symptom burden and complications despite moderate recurrence. Patients with multiple repeated procedures found to have better success rate and outcomes. The complications are not high leading to increased feasibility of the procedure. More research using latest techniques in catheter ablation need to be studied.
肥厚型心肌病（HCM）是最常见的遗传性心血管疾病之一，影响一般人群中的每 500 人中有 1 人。心房颤动的发生率为每年每 100 例患者 3.8%，HCM 患者的总体患病率为 27.09%。患有心房颤动的 HCM 患者死亡风险更高。此类患者中风和其他血栓栓塞风险增加。主要使用β受体阻滞剂或胺碘酮进行的药物治疗产生了不同的结果和高复发率。导管消融术降低了症状负担和并发症，尽管复发率中等。发现多次重复手术的患者成功率和结果更好。并发症并不高，从而提高了手术的可行性。需要研究更多使用导管消融术最新技术的研究。
